KR101770785B1 - 종양 세포 증식 억제를 위해 개선된 조성물 - Google Patents

종양 세포 증식 억제를 위해 개선된 조성물 Download PDF

Info

Publication number
KR101770785B1
KR101770785B1 KR1020127021390A KR20127021390A KR101770785B1 KR 101770785 B1 KR101770785 B1 KR 101770785B1 KR 1020127021390 A KR1020127021390 A KR 1020127021390A KR 20127021390 A KR20127021390 A KR 20127021390A KR 101770785 B1 KR101770785 B1 KR 101770785B1
Authority
KR
South Korea
Prior art keywords
cells
tumor
inflammatory
mature
dcs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020127021390A
Other languages
English (en)
Korean (ko)
Other versions
KR20120114358A (ko
Inventor
알렉스 칼슨-파라
벵트 안데르손
안나카린 월그렌
Original Assignee
이뮤니쿰 에이비
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 이뮤니쿰 에이비 filed Critical 이뮤니쿰 에이비
Publication of KR20120114358A publication Critical patent/KR20120114358A/ko
Application granted granted Critical
Publication of KR101770785B1 publication Critical patent/KR101770785B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/45—Bacterial antigens
    • A61K40/4532—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Developmental Biology & Embryology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020127021390A 2010-02-10 2011-02-10 종양 세포 증식 억제를 위해 개선된 조성물 Active KR101770785B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US30315310P 2010-02-10 2010-02-10
SE1050133 2010-02-10
SE1050133-6 2010-02-10
US61/303,153 2010-02-10
PCT/EP2011/051952 WO2011098516A1 (en) 2010-02-10 2011-02-10 Improved composition for inhibiting tumor cell proliferation

Publications (2)

Publication Number Publication Date
KR20120114358A KR20120114358A (ko) 2012-10-16
KR101770785B1 true KR101770785B1 (ko) 2017-08-23

Family

ID=43903832

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020127021390A Active KR101770785B1 (ko) 2010-02-10 2011-02-10 종양 세포 증식 억제를 위해 개선된 조성물

Country Status (13)

Country Link
US (1) US9034317B2 (enExample)
EP (1) EP2534242B1 (enExample)
JP (1) JP5855018B2 (enExample)
KR (1) KR101770785B1 (enExample)
CN (1) CN102782123B (enExample)
BR (1) BR112012019267B1 (enExample)
DK (1) DK2534242T3 (enExample)
ES (1) ES2581277T3 (enExample)
HU (1) HUE028352T2 (enExample)
PL (1) PL2534242T3 (enExample)
RU (1) RU2565542C2 (enExample)
SI (1) SI2534242T1 (enExample)
WO (1) WO2011098516A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2591230T3 (es) 2012-12-18 2016-11-25 Immunicum Ab Co-diferenciación y activación de monocitos procedentes de donantes alogénicos para producir células dendríticas pro-inflamatorias
AU2016259020B2 (en) * 2015-05-07 2021-12-09 Baylor College Of Medicine Dendritic cell immunotherapy
CN105695403A (zh) * 2015-12-31 2016-06-22 深圳市中美康士生物科技有限公司 一种杀伤性免疫细胞的培养方法及其应用
CN105462926A (zh) * 2015-12-31 2016-04-06 深圳市中美康士生物科技有限公司 一种免疫细胞瘤苗的制备方法及其应用
CN107574149B (zh) * 2016-07-05 2022-02-18 上海细胞治疗研究院 一种树突状细胞的促成熟方法及其用途
CN106085960A (zh) * 2016-07-28 2016-11-09 广州赛莱拉干细胞科技股份有限公司 一种培养dc细胞的培养基及培养方法
CA3037882A1 (en) * 2016-09-23 2018-03-29 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of preparing an isolated population of dendritic cells and methods of treating cancer using same
GB201711379D0 (en) 2017-07-14 2017-08-30 Univ Cape Town Maturation of dendritic cells
SI3460052T1 (sl) * 2017-09-20 2020-03-31 Immunicum Ab Izboljšane alogene dendritične celice za uporabo pri zdravljenju raka

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040214783A1 (en) * 2002-05-08 2004-10-28 Terman David S. Compositions and methods for treatment of neoplastic disease
WO2004053072A2 (en) * 2002-12-06 2004-06-24 Northwest Biotherapeutics, Inc. Administration of dendritic cells partially matured in vitro for the treatment of tumors
EP1840206A1 (en) * 2006-03-28 2007-10-03 Gsf-Forschungszentrum Für Umwelt Und Gesundheit, Gmbh Compositions for the preparation of mature dendritic cells
WO2008110569A1 (en) 2007-03-12 2008-09-18 Bioneer A/S Method for determination of immunomodulatory effect
CN101883845B (zh) 2007-10-08 2015-06-10 英特瑞克斯顿股份有限公司 工程树突细胞及其在癌症治疗中的应用
WO2010065876A2 (en) * 2008-12-06 2010-06-10 The Board Of Regents Of The University Of Texas System Methods and compositions related to th-1 dendritic cells
CN101481677B (zh) * 2009-01-22 2011-12-14 复旦大学附属华山医院 体外刺激树突状细胞成熟的方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Cancer Immunol Immunother. 2008, 57, 1589-1597.*

Also Published As

Publication number Publication date
DK2534242T3 (en) 2016-07-18
EP2534242A1 (en) 2012-12-19
WO2011098516A1 (en) 2011-08-18
RU2565542C2 (ru) 2015-10-20
PL2534242T3 (pl) 2016-11-30
US20120328662A1 (en) 2012-12-27
BR112012019267A2 (pt) 2020-10-06
HUE028352T2 (en) 2016-12-28
JP5855018B2 (ja) 2016-02-09
CN102782123A (zh) 2012-11-14
SI2534242T1 (sl) 2016-08-31
CN102782123B (zh) 2016-05-11
KR20120114358A (ko) 2012-10-16
BR112012019267B1 (pt) 2022-03-03
ES2581277T3 (es) 2016-09-05
JP2013519363A (ja) 2013-05-30
US9034317B2 (en) 2015-05-19
EP2534242B1 (en) 2016-04-20
RU2012137173A (ru) 2014-03-20

Similar Documents

Publication Publication Date Title
KR101770785B1 (ko) 종양 세포 증식 억제를 위해 개선된 조성물
AU2007229640B2 (en) Compositions for the preparation of mature dendritic cells
KR20120093978A (ko) 항원 특이적 ｔ 세포의 증식 방법
EP3353287B1 (en) Compositions and methods for producing dendritic cells
US20200121745A1 (en) Compositions and methods for cancer therapy with dengue virus and dendritic cells
IL292009A (en) In vitro methods and compositions for enhancing the activation of dendritic cells and t cells, and for inducing a th-1 immune response
EP1959007A1 (en) Method for providing mature dendritic cells
Cui et al. Immune responsiveness in a mouse model of combined adoptive immunotherapy with NK and dendritic cells
EP2847321B1 (en) Method for the in vitro maturation of dendritic cells
US10716810B2 (en) Canine autologous immunotherapy using dendritic cell induced cancer killing immunocytes
CN118685356A (zh) 具有免疫增强功能的树突细胞外泌体及其应用
Hori et al. Engulfing tumors with synthetic extracellular matrices for cancer
HK1145155A (en) The use for enhancing antigen immunogenicity and innate and adaptive immunity
HK1089336A (en) Rapid one-step method for generation of antigen loaded dendritic cell vaccine from precursors

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 9